Toremifene and tamoxifen have similar efficacy in the treatment of patients with breast cancer: a meta-analysis of randomized trials
- PMID: 24390230
- DOI: 10.1007/s11033-013-2914-7
Toremifene and tamoxifen have similar efficacy in the treatment of patients with breast cancer: a meta-analysis of randomized trials
Abstract
A meta-analysis of randomized trials was performed to compare the efficacy of toremifene (TOR) with tamoxifen (TAM) in patients with breast cancer. A total of 4,768 intention-to-treat patients from nine randomized trials were identified, with 2,587 patients in TOR group and 2,181 patients in TAM group. The primary outcomes were objective response rate (ORR), time to progression (TTP), and overall survival (OS). The ORR for TOR group was 26.2 % (303/1,156), whereas the ORR for TAM group was 25.2 % (284/1,128). The pooled RR suggested that the ORR were not statistically different between the two therapeutic groups (RR 1.04, 95 % CI 0.91-1.20, P = 0.57). The median TTP was 6.7 months for the TOR group and 9.7 months for the TAM group. The median OS was 30.1 months for the TOR group and 31.7 months for the TAM group. There were no significant difference in TTP and OS between two therapeutic groups (for TTP: HR 0.91, 95 % CI 0.82-1.00; for OS: HR 1.02, 95 % CI 0.91-1.15). Adverse events were generally similar in two therapeutic groups, but TOR may cause fewer vaginal bleeding (4.0 vs. 6.7 %, P < 0.01), headache (0.2 vs. 3.1 %, P = 0.02) and thromboembolic events (4.7 vs. 7.0 %, P = 0.04). Sensitivity analyses were performed by deleting a single study each time; all the results were not materially altered. In summary, the results of this meta-analysis suggest that TOR and TAM have similar efficacy in the treatment of patients with breast cancer.
Similar articles
-
Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.Br J Cancer. 1997;76(2):270-7. doi: 10.1038/bjc.1997.375. Br J Cancer. 1997. PMID: 9231932 Free PMC article. Clinical Trial.
-
[Results of phase II clinical trial of Tamoxifen and Toremifen in two different doses in advanced breast cancer in postmenopausal women].Vopr Onkol. 1997;43(6):587-95. Vopr Onkol. 1997. PMID: 9479357 Clinical Trial. Russian.
-
Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer.Breast Cancer Res Treat. 1999 Jul;56(2):133-43. doi: 10.1023/a:1006250213357. Breast Cancer Res Treat. 1999. PMID: 10573106
-
Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials.Breast Cancer Res Treat. 2011 Aug;128(3):625-31. doi: 10.1007/s10549-011-1556-5. Epub 2011 May 7. Breast Cancer Res Treat. 2011. PMID: 21553116 Review.
-
Adjuvant trials of toremifene vs tamoxifen: the European experience.Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):23-7. Oncology (Williston Park). 1998. PMID: 9556787 Review.
Cited by
-
A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis.BMC Cancer. 2020 Jul 16;20(1):663. doi: 10.1186/s12885-020-07156-x. BMC Cancer. 2020. PMID: 32677982 Free PMC article. Clinical Trial.
-
Targeting BKCa Channels in Migraine: Rationale and Perspectives.CNS Drugs. 2020 Apr;34(4):325-335. doi: 10.1007/s40263-020-00706-8. CNS Drugs. 2020. PMID: 32060729 Review.
-
Breast Cancer Treatments: Updates and New Challenges.J Pers Med. 2021 Aug 19;11(8):808. doi: 10.3390/jpm11080808. J Pers Med. 2021. PMID: 34442452 Free PMC article. Review.
-
High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review.Medicine (Baltimore). 2018 Jun;97(24):e11115. doi: 10.1097/MD.0000000000011115. Medicine (Baltimore). 2018. PMID: 29901634 Free PMC article. Review.
-
Estrogen Receptors as Molecular Targets of Endocrine Therapy for Glioblastoma.Int J Mol Sci. 2021 Nov 17;22(22):12404. doi: 10.3390/ijms222212404. Int J Mol Sci. 2021. PMID: 34830286 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical